Answers are grounded in this paper and cite their sources.
// Mi-Sook Lee 1, 2, * , Ryong Nam Kim 3, 4, * , Hoseok I 5, 6 , Doo-Yi Oh 1, 2 , Ji-Young Song 2 , Ka-Won Noh 1, 2 , Yu-Jin Kim 1, 2 , Jung Wook Yang 11 , Maruja E. Lira 7 , Chang Hun Lee 8 , Min Ki Lee 9 , Yeoung Dae Kim 5 , Mao Mao 7, 13 , Joungho Han 10 , Jhingook Kim 12 , Yoon-La Choi 1, 2, 10 1 Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Laboratory of Cancer Genomics and Molecular Pathology, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea 3 Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea 4 Tumor Microenvironment Global Core Research Center, Seoul National University, Seoul, Korea 5 Department of Thoracic and Cardiovascular Surgery, Pusan National University School of Medicine, Busan, Korea 6 Pusan National University Hospital Biomedical Research Institute, Busan, Korea 7 Pfizer Oncology, San Diego, California, USA 8 Department of Pathology, Pusan National University School of Medicine, Busan, Korea 9 Department of Pulmonology Allergy and Critical Care Medicine, Pusan National University School of Medicine, Busan, Korea 10 Departments of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea 11 Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Korea 12 Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea 13 Present address: BGI Genomics, Shenzhen, China * These authors contributed equally to this work Correspondence to: Yoon-La Choi, email: ylachoi@skku.edu Jhingook Kim, email: jhingookkim@gmail.com Keywords: lung cancer, RET, KIAA1217, KIAA1217-RET fusion, oncogenic driver Received: November 16, 2015 Accepted: April 16, 2016 Published: May 02, 2016 ABSTRACT REarranged during Transfection ( RET ) fusion genes are detected in approximately 1% of lung adenocarcinomas and known primarily as oncogenic driver factors. Here, we found a novel RET fusion gene, KIAA1217-RET , and examined the functional differences of RET51 and RET9 protein, fused with KIAA1217 in cancer progression and drug response. KIAA1217-RET , resulting from the rearrangement of chromosome 10, was generated by the fusion of KIAA1217 exon 11 and RET exon 11 from a non-small cell lung cancer patient. Expression of this gene led to increased cell growth and invasive properties through activations of the PI3K/AKT and ERK signaling pathways and subsequently enabled oncogenic transformation of lung cells. We observed that cells expressing KIAA1217-RET9 fusion protein were more sensitive to vandetanib than those expressing KIAA1217-RET51 and both isoforms attenuated cellular growth via cell cycle arrest. These results demonstrated that KIAA1217-RET fusion represents a novel oncogenic driver gene, the products of which are sensitive to vandetanib treatment, and suggested that the KIAA1217-RET -fusion gene is a promising target for lung cancer treatment.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: